nodes	percent_of_prediction	percent_of_DWPC	metapath
Afatinib—Gefitinib—Lapatinib—breast cancer	0.249	1	CrCrCtD
Afatinib—ERBB2—Lapatinib—breast cancer	0.123	0.41	CbGbCtD
Afatinib—ERBB4—breast cancer	0.0913	0.331	CbGaD
Afatinib—ERBB4—Lapatinib—breast cancer	0.0887	0.296	CbGbCtD
Afatinib—ERBB2—breast cancer	0.0674	0.244	CbGaD
Afatinib—ABL1—breast cancer	0.0524	0.19	CbGaD
Afatinib—EGFR—Lapatinib—breast cancer	0.0405	0.135	CbGbCtD
Afatinib—EGFR—breast cancer	0.0319	0.116	CbGaD
Afatinib—ABCG2—breast cancer	0.0233	0.0844	CbGaD
Afatinib—EGFR—Docetaxel—breast cancer	0.0114	0.0381	CbGbCtD
Afatinib—ABCB1—breast cancer	0.00969	0.0351	CbGaD
Afatinib—ABCG2—Tamoxifen—breast cancer	0.00335	0.0112	CbGbCtD
Afatinib—ABCB1—Toremifene—breast cancer	0.0033	0.011	CbGbCtD
Afatinib—ABCG2—Mitoxantrone—breast cancer	0.00326	0.0109	CbGbCtD
Afatinib—ABCG2—Paclitaxel—breast cancer	0.00261	0.0087	CbGbCtD
Afatinib—ABCG2—Irinotecan—breast cancer	0.00257	0.00858	CbGbCtD
Afatinib—ABCG2—Fluorouracil—breast cancer	0.00247	0.00824	CbGbCtD
Afatinib—ABCG2—Carboplatin—breast cancer	0.00245	0.00819	CbGbCtD
Afatinib—ABCB1—Lapatinib—breast cancer	0.00241	0.00805	CbGbCtD
Afatinib—ABCG2—Docetaxel—breast cancer	0.00188	0.00629	CbGbCtD
Afatinib—ABCG2—Doxorubicin—breast cancer	0.0014	0.00469	CbGbCtD
Afatinib—ABCG2—Methotrexate—breast cancer	0.00136	0.00454	CbGbCtD
Afatinib—ABCB1—Vinorelbine—breast cancer	0.00134	0.00446	CbGbCtD
Afatinib—ABCB1—Tamoxifen—breast cancer	0.00121	0.00403	CbGbCtD
Afatinib—ABCB1—Mitoxantrone—breast cancer	0.00118	0.00393	CbGbCtD
Afatinib—ABCB1—Gemcitabine—breast cancer	0.00104	0.00347	CbGbCtD
Afatinib—ERBB4—mammary gland—breast cancer	0.000975	0.0331	CbGeAlD
Afatinib—ERBB2—mammary gland—breast cancer	0.000975	0.0331	CbGeAlD
Afatinib—ABCB1—Paclitaxel—breast cancer	0.000939	0.00314	CbGbCtD
Afatinib—DYRK1A—mammary gland—breast cancer	0.000938	0.0318	CbGeAlD
Afatinib—ABCB1—Irinotecan—breast cancer	0.000927	0.00309	CbGbCtD
Afatinib—EGFR—mammary gland—breast cancer	0.000827	0.028	CbGeAlD
Afatinib—ABCB1—Vinblastine—breast cancer	0.000824	0.00275	CbGbCtD
Afatinib—ERBB2—nipple—breast cancer	0.000806	0.0274	CbGeAlD
Afatinib—ABCB1—Docetaxel—breast cancer	0.000679	0.00227	CbGbCtD
Afatinib—ERBB2—embryo—breast cancer	0.000665	0.0226	CbGeAlD
Afatinib—ERBB4—embryo—breast cancer	0.000665	0.0226	CbGeAlD
Afatinib—HIPK4—female reproductive system—breast cancer	0.000589	0.02	CbGeAlD
Afatinib—LCK—nipple—breast cancer	0.000588	0.02	CbGeAlD
Afatinib—BLK—adrenal gland—breast cancer	0.000574	0.0195	CbGeAlD
Afatinib—ERBB4—epithelium—breast cancer	0.000543	0.0184	CbGeAlD
Afatinib—ERBB2—epithelium—breast cancer	0.000543	0.0184	CbGeAlD
Afatinib—ERBB2—skin of body—breast cancer	0.000516	0.0175	CbGeAlD
Afatinib—ABCB1—Doxorubicin—breast cancer	0.000506	0.00169	CbGbCtD
Afatinib—HIPK4—endocrine gland—breast cancer	0.000498	0.0169	CbGeAlD
Afatinib—ABCB1—Methotrexate—breast cancer	0.00049	0.00164	CbGbCtD
Afatinib—PHKG2—adipose tissue—breast cancer	0.000488	0.0166	CbGeAlD
Afatinib—ERBB2—endometrium—breast cancer	0.000487	0.0165	CbGeAlD
Afatinib—EPHA6—female reproductive system—breast cancer	0.000465	0.0158	CbGeAlD
Afatinib—ERBB2—uterus—breast cancer	0.000449	0.0152	CbGeAlD
Afatinib—PHKG2—female reproductive system—breast cancer	0.000449	0.0152	CbGeAlD
Afatinib—ERBB4—pituitary gland—breast cancer	0.000441	0.0149	CbGeAlD
Afatinib—ERBB2—adipose tissue—breast cancer	0.000439	0.0149	CbGeAlD
Afatinib—ERBB4—adipose tissue—breast cancer	0.000439	0.0149	CbGeAlD
Afatinib—PHKG2—adrenal gland—breast cancer	0.000438	0.0148	CbGeAlD
Afatinib—DYRK1A—adipose tissue—breast cancer	0.000422	0.0143	CbGeAlD
Afatinib—ABL1—mammary gland—breast cancer	0.000409	0.0139	CbGeAlD
Afatinib—PHKG2—female gonad—breast cancer	0.000408	0.0138	CbGeAlD
Afatinib—ERBB4—female reproductive system—breast cancer	0.000403	0.0137	CbGeAlD
Afatinib—ERBB2—female reproductive system—breast cancer	0.000403	0.0137	CbGeAlD
Afatinib—EPHA6—endocrine gland—breast cancer	0.000394	0.0134	CbGeAlD
Afatinib—ERBB2—adrenal gland—breast cancer	0.000394	0.0133	CbGeAlD
Afatinib—DYRK1A—female reproductive system—breast cancer	0.000388	0.0132	CbGeAlD
Afatinib—EGFR—uterus—breast cancer	0.00038	0.0129	CbGeAlD
Afatinib—PHKG2—endocrine gland—breast cancer	0.00038	0.0129	CbGeAlD
Afatinib—DYRK1A—adrenal gland—breast cancer	0.000379	0.0129	CbGeAlD
Afatinib—EGFR—adipose tissue—breast cancer	0.000372	0.0126	CbGeAlD
Afatinib—ERBB2—female gonad—breast cancer	0.000367	0.0124	CbGeAlD
Afatinib—DYRK1A—female gonad—breast cancer	0.000353	0.012	CbGeAlD
Afatinib—BLK—lymph node—breast cancer	0.000344	0.0117	CbGeAlD
Afatinib—ERBB2—endocrine gland—breast cancer	0.000341	0.0116	CbGeAlD
Afatinib—ERBB4—endocrine gland—breast cancer	0.000341	0.0116	CbGeAlD
Afatinib—ABL1—nipple—breast cancer	0.000338	0.0115	CbGeAlD
Afatinib—EGFR—adrenal gland—breast cancer	0.000334	0.0113	CbGeAlD
Afatinib—DYRK1A—endocrine gland—breast cancer	0.000329	0.0111	CbGeAlD
Afatinib—IRAK1—adipose tissue—breast cancer	0.000328	0.0111	CbGeAlD
Afatinib—LCK—uterus—breast cancer	0.000327	0.0111	CbGeAlD
Afatinib—LCK—adipose tissue—breast cancer	0.00032	0.0109	CbGeAlD
Afatinib—EGFR—female gonad—breast cancer	0.000311	0.0106	CbGeAlD
Afatinib—IRAK1—female reproductive system—breast cancer	0.000302	0.0102	CbGeAlD
Afatinib—IRAK1—adrenal gland—breast cancer	0.000294	0.00999	CbGeAlD
Afatinib—LCK—adrenal gland—breast cancer	0.000287	0.00974	CbGeAlD
Afatinib—IRAK1—bone marrow—breast cancer	0.000285	0.00966	CbGeAlD
Afatinib—ABL1—embryo—breast cancer	0.000279	0.00946	CbGeAlD
Afatinib—LCK—bone marrow—breast cancer	0.000278	0.00942	CbGeAlD
Afatinib—IRAK1—female gonad—breast cancer	0.000275	0.00931	CbGeAlD
Afatinib—LCK—female gonad—breast cancer	0.000268	0.00908	CbGeAlD
Afatinib—PHKG2—lymph node—breast cancer	0.000262	0.0089	CbGeAlD
Afatinib—Gefitinib—CHEK2—breast cancer	0.00026	0.12	CrCbGaD
Afatinib—Vandetanib—ERBB3—breast cancer	0.000244	0.113	CrCbGaD
Afatinib—ERBB2—lymph node—breast cancer	0.000236	0.008	CbGeAlD
Afatinib—Gefitinib—ERBB3—breast cancer	0.000232	0.107	CrCbGaD
Afatinib—DYRK1A—lymph node—breast cancer	0.000227	0.0077	CbGeAlD
Afatinib—ABL1—skin of body—breast cancer	0.000216	0.00734	CbGeAlD
Afatinib—DYRK1A—Topotecan—Irinotecan—breast cancer	0.000206	0.118	CbGdCrCtD
Afatinib—ABL1—endometrium—breast cancer	0.000204	0.00692	CbGeAlD
Afatinib—EGFR—lymph node—breast cancer	0.0002	0.00678	CbGeAlD
Afatinib—ABL1—uterus—breast cancer	0.000188	0.00638	CbGeAlD
Afatinib—ABL1—pituitary gland—breast cancer	0.000185	0.00626	CbGeAlD
Afatinib—ABL1—adipose tissue—breast cancer	0.000184	0.00624	CbGeAlD
Afatinib—Vandetanib—ABL1—breast cancer	0.00018	0.0832	CrCbGaD
Afatinib—IRAK1—lymph node—breast cancer	0.000176	0.00599	CbGeAlD
Afatinib—LCK—lymph node—breast cancer	0.000172	0.00584	CbGeAlD
Afatinib—ABL1—female reproductive system—breast cancer	0.000169	0.00573	CbGeAlD
Afatinib—ABL1—adrenal gland—breast cancer	0.000165	0.00559	CbGeAlD
Afatinib—Vandetanib—SRC—breast cancer	0.000163	0.0753	CrCbGaD
Afatinib—ABL1—bone marrow—breast cancer	0.00016	0.00541	CbGeAlD
Afatinib—ERBB2—Topotecan—Irinotecan—breast cancer	0.000158	0.0906	CbGdCrCtD
Afatinib—ABL1—female gonad—breast cancer	0.000154	0.00522	CbGeAlD
Afatinib—Vandetanib—KDR—breast cancer	0.000153	0.0707	CrCbGaD
Afatinib—Vandetanib—ABCC1—breast cancer	0.000152	0.0701	CrCbGaD
Afatinib—ABL1—endocrine gland—breast cancer	0.000143	0.00485	CbGeAlD
Afatinib—Vandetanib—VEGFA—breast cancer	0.00013	0.06	CrCbGaD
Afatinib—ABCG2—endometrium—breast cancer	0.000129	0.00436	CbGeAlD
Afatinib—ABCG2—uterus—breast cancer	0.000119	0.00402	CbGeAlD
Afatinib—ABL1—Topotecan—Irinotecan—breast cancer	0.000118	0.0677	CbGdCrCtD
Afatinib—ABCG2—pituitary gland—breast cancer	0.000116	0.00395	CbGeAlD
Afatinib—ABCG2—adipose tissue—breast cancer	0.000116	0.00393	CbGeAlD
Afatinib—Vandetanib—EGFR—breast cancer	0.00011	0.0506	CrCbGaD
Afatinib—DYRK1A—Epirubicin—Idarubicin—breast cancer	0.000105	0.0603	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Idarubicin—breast cancer	0.000105	0.0603	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Idarubicin—breast cancer	0.000105	0.0603	CbGdCrCtD
Afatinib—Gefitinib—EGFR—breast cancer	0.000104	0.0481	CrCbGaD
Afatinib—ABCG2—adrenal gland—breast cancer	0.000104	0.00353	CbGeAlD
Afatinib—ABCG2—bone marrow—breast cancer	0.000101	0.00341	CbGeAlD
Afatinib—ABL1—lymph node—breast cancer	9.89e-05	0.00335	CbGeAlD
Afatinib—ABCG2—female gonad—breast cancer	9.7e-05	0.00329	CbGeAlD
Afatinib—ABCB1—embryo—breast cancer	8.67e-05	0.00294	CbGeAlD
Afatinib—ERBB2—Epirubicin—Idarubicin—breast cancer	8.1e-05	0.0464	CbGdCrCtD
Afatinib—ERBB2—Doxorubicin—Idarubicin—breast cancer	8.1e-05	0.0464	CbGdCrCtD
Afatinib—Vandetanib—ABCG2—breast cancer	8e-05	0.037	CrCbGaD
Afatinib—Gefitinib—ABCG2—breast cancer	7.6e-05	0.0351	CrCbGaD
Afatinib—ABCB1—epithelium—breast cancer	7.07e-05	0.0024	CbGeAlD
Afatinib—ABCB1—endometrium—breast cancer	6.34e-05	0.00215	CbGeAlD
Afatinib—ABCG2—lymph node—breast cancer	6.23e-05	0.00211	CbGeAlD
Afatinib—ABL1—Epirubicin—Idarubicin—breast cancer	6.05e-05	0.0346	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Idarubicin—breast cancer	6.05e-05	0.0346	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Idarubicin—breast cancer	6.05e-05	0.0346	CbGdCrCtD
Afatinib—Gefitinib—CYP1A1—breast cancer	5.95e-05	0.0275	CrCbGaD
Afatinib—ABCB1—uterus—breast cancer	5.85e-05	0.00198	CbGeAlD
Afatinib—ABCB1—pituitary gland—breast cancer	5.74e-05	0.00195	CbGeAlD
Afatinib—ABCB1—adipose tissue—breast cancer	5.72e-05	0.00194	CbGeAlD
Afatinib—ABCB1—female reproductive system—breast cancer	5.26e-05	0.00178	CbGeAlD
Afatinib—ABCB1—adrenal gland—breast cancer	5.13e-05	0.00174	CbGeAlD
Afatinib—ABCB1—bone marrow—breast cancer	4.96e-05	0.00168	CbGeAlD
Afatinib—DYRK1A—Idarubicin—Epirubicin—breast cancer	4.84e-05	0.0277	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Epirubicin—breast cancer	4.84e-05	0.0277	CbGdCrCtD
Afatinib—DYRK1A—Doxorubicin—Epirubicin—breast cancer	4.84e-05	0.0277	CbGdCrCtD
Afatinib—ERBB2—Triamcinolone—Fluoxymesterone—breast cancer	4.8e-05	0.0275	CbGdCrCtD
Afatinib—ABCB1—female gonad—breast cancer	4.78e-05	0.00162	CbGeAlD
Afatinib—ERBB2—Desoximetasone—Fluoxymesterone—breast cancer	4.56e-05	0.0261	CbGdCrCtD
Afatinib—DYRK1A—Idarubicin—Doxorubicin—breast cancer	4.48e-05	0.0256	CbGdCrCtD
Afatinib—DYRK1A—Daunorubicin—Doxorubicin—breast cancer	4.48e-05	0.0256	CbGdCrCtD
Afatinib—DYRK1A—Epirubicin—Doxorubicin—breast cancer	4.48e-05	0.0256	CbGdCrCtD
Afatinib—ABCB1—endocrine gland—breast cancer	4.45e-05	0.00151	CbGeAlD
Afatinib—Gefitinib—CYP2D6—breast cancer	4.43e-05	0.0205	CrCbGaD
Afatinib—Vandetanib—CYP3A4—breast cancer	4e-05	0.0185	CrCbGaD
Afatinib—Gefitinib—CYP3A4—breast cancer	3.8e-05	0.0176	CrCbGaD
Afatinib—ERBB2—Doxorubicin—Epirubicin—breast cancer	3.72e-05	0.0213	CbGdCrCtD
Afatinib—Vandetanib—ALB—breast cancer	3.49e-05	0.0161	CrCbGaD
Afatinib—ERBB2—Epirubicin—Doxorubicin—breast cancer	3.44e-05	0.0197	CbGdCrCtD
Afatinib—Gefitinib—ALB—breast cancer	3.32e-05	0.0153	CrCbGaD
Afatinib—Gefitinib—ABCB1—breast cancer	3.16e-05	0.0146	CrCbGaD
Afatinib—ABCB1—lymph node—breast cancer	3.07e-05	0.00104	CbGeAlD
Afatinib—Dehydration—Doxorubicin—breast cancer	2.88e-05	0.000438	CcSEcCtD
Afatinib—Muscle spasms—Docetaxel—breast cancer	2.88e-05	0.000437	CcSEcCtD
Afatinib—Upper respiratory tract infection—Methotrexate—breast cancer	2.88e-05	0.000437	CcSEcCtD
Afatinib—Infection—Paclitaxel—breast cancer	2.86e-05	0.000435	CcSEcCtD
Afatinib—Dry skin—Doxorubicin—breast cancer	2.84e-05	0.000432	CcSEcCtD
Afatinib—Nausea—Goserelin—breast cancer	2.84e-05	0.000432	CcSEcCtD
Afatinib—Dysgeusia—Capecitabine—breast cancer	2.84e-05	0.000431	CcSEcCtD
Afatinib—Dizziness—Vinorelbine—breast cancer	2.83e-05	0.00043	CcSEcCtD
Afatinib—Nervous system disorder—Paclitaxel—breast cancer	2.83e-05	0.000429	CcSEcCtD
Afatinib—Hypokalaemia—Doxorubicin—breast cancer	2.82e-05	0.000429	CcSEcCtD
Afatinib—Back pain—Capecitabine—breast cancer	2.8e-05	0.000426	CcSEcCtD
Afatinib—Diarrhoea—Thiotepa—breast cancer	2.8e-05	0.000425	CcSEcCtD
Afatinib—Skin disorder—Paclitaxel—breast cancer	2.8e-05	0.000425	CcSEcCtD
Afatinib—Body temperature increased—Irinotecan—breast cancer	2.79e-05	0.000424	CcSEcCtD
Afatinib—Body temperature increased—Mitoxantrone—breast cancer	2.79e-05	0.000424	CcSEcCtD
Afatinib—Aspartate aminotransferase increased—Doxorubicin—breast cancer	2.79e-05	0.000424	CcSEcCtD
Afatinib—Muscle spasms—Capecitabine—breast cancer	2.79e-05	0.000423	CcSEcCtD
Afatinib—ABL1—Idarubicin—Epirubicin—breast cancer	2.78e-05	0.0159	CbGdCrCtD
Afatinib—ABL1—Doxorubicin—Epirubicin—breast cancer	2.78e-05	0.0159	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Epirubicin—breast cancer	2.78e-05	0.0159	CbGdCrCtD
Afatinib—Pneumonia—Methotrexate—breast cancer	2.78e-05	0.000422	CcSEcCtD
Afatinib—Nasopharyngitis—Doxorubicin—breast cancer	2.77e-05	0.000421	CcSEcCtD
Afatinib—Infestation NOS—Methotrexate—breast cancer	2.76e-05	0.000419	CcSEcCtD
Afatinib—Infestation—Methotrexate—breast cancer	2.76e-05	0.000419	CcSEcCtD
Afatinib—Alanine aminotransferase increased—Doxorubicin—breast cancer	2.74e-05	0.000415	CcSEcCtD
Afatinib—Vomiting—Vinorelbine—breast cancer	2.72e-05	0.000414	CcSEcCtD
Afatinib—Body temperature increased—Gemcitabine—breast cancer	2.72e-05	0.000413	CcSEcCtD
Afatinib—Renal failure—Methotrexate—breast cancer	2.71e-05	0.000412	CcSEcCtD
Afatinib—Dizziness—Thiotepa—breast cancer	2.71e-05	0.000411	CcSEcCtD
Afatinib—Rash—Vinorelbine—breast cancer	2.7e-05	0.00041	CcSEcCtD
Afatinib—Dermatitis—Vinorelbine—breast cancer	2.7e-05	0.00041	CcSEcCtD
Afatinib—Upper respiratory tract infection—Epirubicin—breast cancer	2.69e-05	0.000409	CcSEcCtD
Afatinib—Stomatitis—Methotrexate—breast cancer	2.69e-05	0.000409	CcSEcCtD
Afatinib—Headache—Vinorelbine—breast cancer	2.68e-05	0.000408	CcSEcCtD
Afatinib—Conjunctivitis—Methotrexate—breast cancer	2.68e-05	0.000407	CcSEcCtD
Afatinib—Body temperature increased—Fluorouracil—breast cancer	2.67e-05	0.000406	CcSEcCtD
Afatinib—Weight decreased—Epirubicin—breast cancer	2.62e-05	0.000398	CcSEcCtD
Afatinib—Cough—Docetaxel—breast cancer	2.61e-05	0.000397	CcSEcCtD
Afatinib—Hepatobiliary disease—Methotrexate—breast cancer	2.61e-05	0.000396	CcSEcCtD
Afatinib—Insomnia—Paclitaxel—breast cancer	2.61e-05	0.000396	CcSEcCtD
Afatinib—Epistaxis—Methotrexate—breast cancer	2.6e-05	0.000395	CcSEcCtD
Afatinib—Vomiting—Thiotepa—breast cancer	2.6e-05	0.000395	CcSEcCtD
Afatinib—Pneumonia—Epirubicin—breast cancer	2.6e-05	0.000395	CcSEcCtD
Afatinib—Infestation NOS—Epirubicin—breast cancer	2.58e-05	0.000392	CcSEcCtD
Afatinib—Infestation—Epirubicin—breast cancer	2.58e-05	0.000392	CcSEcCtD
Afatinib—Rash—Thiotepa—breast cancer	2.58e-05	0.000392	CcSEcCtD
Afatinib—Dermatitis—Thiotepa—breast cancer	2.58e-05	0.000391	CcSEcCtD
Afatinib—ABL1—Idarubicin—Doxorubicin—breast cancer	2.57e-05	0.0147	CbGdCrCtD
Afatinib—ABL1—Epirubicin—Doxorubicin—breast cancer	2.57e-05	0.0147	CbGdCrCtD
Afatinib—ABL1—Daunorubicin—Doxorubicin—breast cancer	2.57e-05	0.0147	CbGdCrCtD
Afatinib—Dyspnoea—Paclitaxel—breast cancer	2.57e-05	0.00039	CcSEcCtD
Afatinib—Headache—Thiotepa—breast cancer	2.56e-05	0.000389	CcSEcCtD
Afatinib—Nausea—Vinorelbine—breast cancer	2.54e-05	0.000386	CcSEcCtD
Afatinib—Renal failure—Epirubicin—breast cancer	2.54e-05	0.000386	CcSEcCtD
Afatinib—Dyspepsia—Paclitaxel—breast cancer	2.54e-05	0.000385	CcSEcCtD
Afatinib—Asthenia—Irinotecan—breast cancer	2.53e-05	0.000385	CcSEcCtD
Afatinib—Asthenia—Mitoxantrone—breast cancer	2.53e-05	0.000385	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—breast cancer	2.53e-05	0.000384	CcSEcCtD
Afatinib—Cough—Capecitabine—breast cancer	2.53e-05	0.000384	CcSEcCtD
Afatinib—Stomatitis—Epirubicin—breast cancer	2.52e-05	0.000382	CcSEcCtD
Afatinib—Conjunctivitis—Epirubicin—breast cancer	2.51e-05	0.000381	CcSEcCtD
Afatinib—Urinary tract infection—Epirubicin—breast cancer	2.51e-05	0.000381	CcSEcCtD
Afatinib—Decreased appetite—Paclitaxel—breast cancer	2.5e-05	0.00038	CcSEcCtD
Afatinib—Upper respiratory tract infection—Doxorubicin—breast cancer	2.49e-05	0.000378	CcSEcCtD
Afatinib—Gastrointestinal disorder—Paclitaxel—breast cancer	2.49e-05	0.000378	CcSEcCtD
Afatinib—Fatigue—Paclitaxel—breast cancer	2.48e-05	0.000377	CcSEcCtD
Afatinib—Asthenia—Gemcitabine—breast cancer	2.47e-05	0.000375	CcSEcCtD
Afatinib—Constipation—Paclitaxel—breast cancer	2.46e-05	0.000374	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—breast cancer	2.45e-05	0.000372	CcSEcCtD
Afatinib—Urinary tract disorder—Methotrexate—breast cancer	2.45e-05	0.000372	CcSEcCtD
Afatinib—Hepatobiliary disease—Epirubicin—breast cancer	2.44e-05	0.000371	CcSEcCtD
Afatinib—Epistaxis—Epirubicin—breast cancer	2.44e-05	0.00037	CcSEcCtD
Afatinib—Pruritus—Gemcitabine—breast cancer	2.43e-05	0.00037	CcSEcCtD
Afatinib—Nausea—Thiotepa—breast cancer	2.43e-05	0.000369	CcSEcCtD
Afatinib—Urethral disorder—Methotrexate—breast cancer	2.43e-05	0.000369	CcSEcCtD
Afatinib—Infection—Docetaxel—breast cancer	2.43e-05	0.000369	CcSEcCtD
Afatinib—Weight decreased—Doxorubicin—breast cancer	2.42e-05	0.000368	CcSEcCtD
Afatinib—Diarrhoea—Irinotecan—breast cancer	2.42e-05	0.000367	CcSEcCtD
Afatinib—Diarrhoea—Mitoxantrone—breast cancer	2.42e-05	0.000367	CcSEcCtD
Afatinib—Pneumonia—Doxorubicin—breast cancer	2.4e-05	0.000365	CcSEcCtD
Afatinib—Nervous system disorder—Docetaxel—breast cancer	2.4e-05	0.000364	CcSEcCtD
Afatinib—Pruritus—Fluorouracil—breast cancer	2.39e-05	0.000364	CcSEcCtD
Afatinib—Infestation—Doxorubicin—breast cancer	2.39e-05	0.000363	CcSEcCtD
Afatinib—Infestation NOS—Doxorubicin—breast cancer	2.39e-05	0.000363	CcSEcCtD
Afatinib—Skin disorder—Docetaxel—breast cancer	2.37e-05	0.00036	CcSEcCtD
Afatinib—Diarrhoea—Gemcitabine—breast cancer	2.35e-05	0.000358	CcSEcCtD
Afatinib—Renal failure—Doxorubicin—breast cancer	2.35e-05	0.000357	CcSEcCtD
Afatinib—Infection—Capecitabine—breast cancer	2.35e-05	0.000357	CcSEcCtD
Afatinib—Dizziness—Irinotecan—breast cancer	2.34e-05	0.000355	CcSEcCtD
Afatinib—Stomatitis—Doxorubicin—breast cancer	2.33e-05	0.000354	CcSEcCtD
Afatinib—Urinary tract infection—Doxorubicin—breast cancer	2.32e-05	0.000353	CcSEcCtD
Afatinib—Conjunctivitis—Doxorubicin—breast cancer	2.32e-05	0.000353	CcSEcCtD
Afatinib—Nervous system disorder—Capecitabine—breast cancer	2.32e-05	0.000352	CcSEcCtD
Afatinib—Eye disorder—Methotrexate—breast cancer	2.32e-05	0.000352	CcSEcCtD
Afatinib—Diarrhoea—Fluorouracil—breast cancer	2.32e-05	0.000352	CcSEcCtD
Afatinib—Skin disorder—Capecitabine—breast cancer	2.3e-05	0.000349	CcSEcCtD
Afatinib—Urinary tract disorder—Epirubicin—breast cancer	2.29e-05	0.000348	CcSEcCtD
Afatinib—Connective tissue disorder—Epirubicin—breast cancer	2.28e-05	0.000346	CcSEcCtD
Afatinib—Body temperature increased—Paclitaxel—breast cancer	2.28e-05	0.000346	CcSEcCtD
Afatinib—Urethral disorder—Epirubicin—breast cancer	2.27e-05	0.000345	CcSEcCtD
Afatinib—Hepatobiliary disease—Doxorubicin—breast cancer	2.26e-05	0.000343	CcSEcCtD
Afatinib—Epistaxis—Doxorubicin—breast cancer	2.25e-05	0.000342	CcSEcCtD
Afatinib—Vomiting—Irinotecan—breast cancer	2.25e-05	0.000341	CcSEcCtD
Afatinib—Vomiting—Mitoxantrone—breast cancer	2.25e-05	0.000341	CcSEcCtD
Afatinib—Dizziness—Fluorouracil—breast cancer	2.24e-05	0.00034	CcSEcCtD
Afatinib—Mediastinal disorder—Methotrexate—breast cancer	2.23e-05	0.000339	CcSEcCtD
Afatinib—Rash—Irinotecan—breast cancer	2.23e-05	0.000338	CcSEcCtD
Afatinib—Rash—Mitoxantrone—breast cancer	2.23e-05	0.000338	CcSEcCtD
Afatinib—Dermatitis—Irinotecan—breast cancer	2.23e-05	0.000338	CcSEcCtD
Afatinib—Dermatitis—Mitoxantrone—breast cancer	2.23e-05	0.000338	CcSEcCtD
Afatinib—Headache—Mitoxantrone—breast cancer	2.21e-05	0.000336	CcSEcCtD
Afatinib—Headache—Irinotecan—breast cancer	2.21e-05	0.000336	CcSEcCtD
Afatinib—Insomnia—Docetaxel—breast cancer	2.21e-05	0.000336	CcSEcCtD
Afatinib—Alopecia—Methotrexate—breast cancer	2.19e-05	0.000333	CcSEcCtD
Afatinib—Vomiting—Gemcitabine—breast cancer	2.19e-05	0.000332	CcSEcCtD
Afatinib—Dyspnoea—Docetaxel—breast cancer	2.18e-05	0.000331	CcSEcCtD
Afatinib—Mental disorder—Methotrexate—breast cancer	2.17e-05	0.00033	CcSEcCtD
Afatinib—Rash—Gemcitabine—breast cancer	2.17e-05	0.00033	CcSEcCtD
Afatinib—Dermatitis—Gemcitabine—breast cancer	2.17e-05	0.000329	CcSEcCtD
Afatinib—Eye disorder—Epirubicin—breast cancer	2.17e-05	0.000329	CcSEcCtD
Afatinib—Malnutrition—Methotrexate—breast cancer	2.16e-05	0.000328	CcSEcCtD
Afatinib—Headache—Gemcitabine—breast cancer	2.16e-05	0.000327	CcSEcCtD
Afatinib—Vomiting—Fluorouracil—breast cancer	2.15e-05	0.000327	CcSEcCtD
Afatinib—Dyspepsia—Docetaxel—breast cancer	2.15e-05	0.000327	CcSEcCtD
Afatinib—Insomnia—Capecitabine—breast cancer	2.14e-05	0.000325	CcSEcCtD
Afatinib—Rash—Fluorouracil—breast cancer	2.13e-05	0.000324	CcSEcCtD
Afatinib—Dermatitis—Fluorouracil—breast cancer	2.13e-05	0.000324	CcSEcCtD
Afatinib—Decreased appetite—Docetaxel—breast cancer	2.12e-05	0.000322	CcSEcCtD
Afatinib—Headache—Fluorouracil—breast cancer	2.12e-05	0.000322	CcSEcCtD
Afatinib—Urinary tract disorder—Doxorubicin—breast cancer	2.12e-05	0.000322	CcSEcCtD
Afatinib—Dysgeusia—Methotrexate—breast cancer	2.11e-05	0.000321	CcSEcCtD
Afatinib—Gastrointestinal disorder—Docetaxel—breast cancer	2.11e-05	0.00032	CcSEcCtD
Afatinib—Connective tissue disorder—Doxorubicin—breast cancer	2.11e-05	0.00032	CcSEcCtD
Afatinib—Dyspnoea—Capecitabine—breast cancer	2.11e-05	0.00032	CcSEcCtD
Afatinib—Fatigue—Docetaxel—breast cancer	2.11e-05	0.00032	CcSEcCtD
Afatinib—Urethral disorder—Doxorubicin—breast cancer	2.1e-05	0.000319	CcSEcCtD
Afatinib—Nausea—Mitoxantrone—breast cancer	2.1e-05	0.000319	CcSEcCtD
Afatinib—Nausea—Irinotecan—breast cancer	2.1e-05	0.000319	CcSEcCtD
Afatinib—Mediastinal disorder—Epirubicin—breast cancer	2.09e-05	0.000317	CcSEcCtD
Afatinib—Constipation—Docetaxel—breast cancer	2.09e-05	0.000317	CcSEcCtD
Afatinib—Back pain—Methotrexate—breast cancer	2.09e-05	0.000317	CcSEcCtD
Afatinib—Dyspepsia—Capecitabine—breast cancer	2.08e-05	0.000316	CcSEcCtD
Afatinib—Asthenia—Paclitaxel—breast cancer	2.07e-05	0.000314	CcSEcCtD
Afatinib—Decreased appetite—Capecitabine—breast cancer	2.06e-05	0.000312	CcSEcCtD
Afatinib—Alopecia—Epirubicin—breast cancer	2.05e-05	0.000311	CcSEcCtD
Afatinib—Nausea—Gemcitabine—breast cancer	2.04e-05	0.00031	CcSEcCtD
Afatinib—Gastrointestinal disorder—Capecitabine—breast cancer	2.04e-05	0.00031	CcSEcCtD
Afatinib—Fatigue—Capecitabine—breast cancer	2.04e-05	0.00031	CcSEcCtD
Afatinib—Pruritus—Paclitaxel—breast cancer	2.04e-05	0.00031	CcSEcCtD
Afatinib—Mental disorder—Epirubicin—breast cancer	2.03e-05	0.000309	CcSEcCtD
Afatinib—Constipation—Capecitabine—breast cancer	2.02e-05	0.000307	CcSEcCtD
Afatinib—Malnutrition—Epirubicin—breast cancer	2.02e-05	0.000307	CcSEcCtD
Afatinib—Nausea—Fluorouracil—breast cancer	2.01e-05	0.000305	CcSEcCtD
Afatinib—Eye disorder—Doxorubicin—breast cancer	2e-05	0.000305	CcSEcCtD
Afatinib—Dysgeusia—Epirubicin—breast cancer	1.98e-05	0.0003	CcSEcCtD
Afatinib—Diarrhoea—Paclitaxel—breast cancer	1.97e-05	0.000299	CcSEcCtD
Afatinib—Back pain—Epirubicin—breast cancer	1.95e-05	0.000297	CcSEcCtD
Afatinib—Muscle spasms—Epirubicin—breast cancer	1.94e-05	0.000295	CcSEcCtD
Afatinib—Mediastinal disorder—Doxorubicin—breast cancer	1.93e-05	0.000294	CcSEcCtD
Afatinib—Body temperature increased—Docetaxel—breast cancer	1.93e-05	0.000293	CcSEcCtD
Afatinib—Dizziness—Paclitaxel—breast cancer	1.91e-05	0.000289	CcSEcCtD
Afatinib—Alopecia—Doxorubicin—breast cancer	1.9e-05	0.000288	CcSEcCtD
Afatinib—Cough—Methotrexate—breast cancer	1.88e-05	0.000286	CcSEcCtD
Afatinib—Mental disorder—Doxorubicin—breast cancer	1.88e-05	0.000285	CcSEcCtD
Afatinib—Body temperature increased—Capecitabine—breast cancer	1.87e-05	0.000284	CcSEcCtD
Afatinib—Malnutrition—Doxorubicin—breast cancer	1.87e-05	0.000284	CcSEcCtD
Afatinib—Vomiting—Paclitaxel—breast cancer	1.83e-05	0.000278	CcSEcCtD
Afatinib—Dysgeusia—Doxorubicin—breast cancer	1.83e-05	0.000278	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—breast cancer	1.82e-05	0.000277	CcSEcCtD
Afatinib—Rash—Paclitaxel—breast cancer	1.82e-05	0.000276	CcSEcCtD
Afatinib—Dermatitis—Paclitaxel—breast cancer	1.82e-05	0.000276	CcSEcCtD
Afatinib—Back pain—Doxorubicin—breast cancer	1.81e-05	0.000274	CcSEcCtD
Afatinib—Headache—Paclitaxel—breast cancer	1.81e-05	0.000274	CcSEcCtD
Afatinib—Muscle spasms—Doxorubicin—breast cancer	1.8e-05	0.000273	CcSEcCtD
Afatinib—Cough—Epirubicin—breast cancer	1.76e-05	0.000268	CcSEcCtD
Afatinib—Asthenia—Docetaxel—breast cancer	1.75e-05	0.000266	CcSEcCtD
Afatinib—Infection—Methotrexate—breast cancer	1.75e-05	0.000266	CcSEcCtD
Afatinib—Pruritus—Docetaxel—breast cancer	1.73e-05	0.000262	CcSEcCtD
Afatinib—Nervous system disorder—Methotrexate—breast cancer	1.73e-05	0.000262	CcSEcCtD
Afatinib—Nausea—Paclitaxel—breast cancer	1.71e-05	0.00026	CcSEcCtD
Afatinib—Skin disorder—Methotrexate—breast cancer	1.71e-05	0.00026	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—breast cancer	1.71e-05	0.000259	CcSEcCtD
Afatinib—Asthenia—Capecitabine—breast cancer	1.7e-05	0.000258	CcSEcCtD
Afatinib—Pruritus—Capecitabine—breast cancer	1.67e-05	0.000254	CcSEcCtD
Afatinib—Diarrhoea—Docetaxel—breast cancer	1.67e-05	0.000254	CcSEcCtD
Afatinib—Infection—Epirubicin—breast cancer	1.64e-05	0.000249	CcSEcCtD
Afatinib—Cough—Doxorubicin—breast cancer	1.63e-05	0.000248	CcSEcCtD
Afatinib—Diarrhoea—Capecitabine—breast cancer	1.62e-05	0.000246	CcSEcCtD
Afatinib—Nervous system disorder—Epirubicin—breast cancer	1.62e-05	0.000245	CcSEcCtD
Afatinib—Dizziness—Docetaxel—breast cancer	1.62e-05	0.000245	CcSEcCtD
Afatinib—Skin disorder—Epirubicin—breast cancer	1.6e-05	0.000243	CcSEcCtD
Afatinib—Insomnia—Methotrexate—breast cancer	1.59e-05	0.000242	CcSEcCtD
Afatinib—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—breast cancer	1.58e-05	0.00024	CcSEcCtD
Afatinib—Dyspnoea—Methotrexate—breast cancer	1.57e-05	0.000238	CcSEcCtD
Afatinib—Dizziness—Capecitabine—breast cancer	1.56e-05	0.000237	CcSEcCtD
Afatinib—Vomiting—Docetaxel—breast cancer	1.55e-05	0.000236	CcSEcCtD
Afatinib—Dyspepsia—Methotrexate—breast cancer	1.55e-05	0.000235	CcSEcCtD
Afatinib—Rash—Docetaxel—breast cancer	1.54e-05	0.000234	CcSEcCtD
Afatinib—Dermatitis—Docetaxel—breast cancer	1.54e-05	0.000234	CcSEcCtD
Afatinib—Decreased appetite—Methotrexate—breast cancer	1.53e-05	0.000232	CcSEcCtD
Afatinib—Headache—Docetaxel—breast cancer	1.53e-05	0.000232	CcSEcCtD
Afatinib—Gastrointestinal disorder—Methotrexate—breast cancer	1.52e-05	0.000231	CcSEcCtD
Afatinib—Fatigue—Methotrexate—breast cancer	1.52e-05	0.000231	CcSEcCtD
Afatinib—Infection—Doxorubicin—breast cancer	1.51e-05	0.00023	CcSEcCtD
Afatinib—Vomiting—Capecitabine—breast cancer	1.5e-05	0.000228	CcSEcCtD
Afatinib—Nervous system disorder—Doxorubicin—breast cancer	1.49e-05	0.000227	CcSEcCtD
Afatinib—Rash—Capecitabine—breast cancer	1.49e-05	0.000226	CcSEcCtD
Afatinib—Insomnia—Epirubicin—breast cancer	1.49e-05	0.000226	CcSEcCtD
Afatinib—Dermatitis—Capecitabine—breast cancer	1.49e-05	0.000226	CcSEcCtD
Afatinib—Headache—Capecitabine—breast cancer	1.48e-05	0.000225	CcSEcCtD
Afatinib—Skin disorder—Doxorubicin—breast cancer	1.48e-05	0.000225	CcSEcCtD
Afatinib—Dyspnoea—Epirubicin—breast cancer	1.47e-05	0.000223	CcSEcCtD
Afatinib—Nausea—Docetaxel—breast cancer	1.45e-05	0.00022	CcSEcCtD
Afatinib—Dyspepsia—Epirubicin—breast cancer	1.45e-05	0.00022	CcSEcCtD
Afatinib—Decreased appetite—Epirubicin—breast cancer	1.43e-05	0.000217	CcSEcCtD
Afatinib—Gastrointestinal disorder—Epirubicin—breast cancer	1.42e-05	0.000216	CcSEcCtD
Afatinib—Fatigue—Epirubicin—breast cancer	1.42e-05	0.000216	CcSEcCtD
Afatinib—Constipation—Epirubicin—breast cancer	1.41e-05	0.000214	CcSEcCtD
Afatinib—Nausea—Capecitabine—breast cancer	1.4e-05	0.000213	CcSEcCtD
Afatinib—Body temperature increased—Methotrexate—breast cancer	1.39e-05	0.000211	CcSEcCtD
Afatinib—Insomnia—Doxorubicin—breast cancer	1.38e-05	0.000209	CcSEcCtD
Afatinib—Dyspnoea—Doxorubicin—breast cancer	1.36e-05	0.000206	CcSEcCtD
Afatinib—Dyspepsia—Doxorubicin—breast cancer	1.34e-05	0.000204	CcSEcCtD
Afatinib—Decreased appetite—Doxorubicin—breast cancer	1.33e-05	0.000201	CcSEcCtD
Afatinib—Gastrointestinal disorder—Doxorubicin—breast cancer	1.32e-05	0.0002	CcSEcCtD
Afatinib—Fatigue—Doxorubicin—breast cancer	1.31e-05	0.0002	CcSEcCtD
Afatinib—Constipation—Doxorubicin—breast cancer	1.3e-05	0.000198	CcSEcCtD
Afatinib—Body temperature increased—Epirubicin—breast cancer	1.3e-05	0.000198	CcSEcCtD
Afatinib—Asthenia—Methotrexate—breast cancer	1.26e-05	0.000192	CcSEcCtD
Afatinib—Pruritus—Methotrexate—breast cancer	1.25e-05	0.000189	CcSEcCtD
Afatinib—Body temperature increased—Doxorubicin—breast cancer	1.2e-05	0.000183	CcSEcCtD
Afatinib—Diarrhoea—Methotrexate—breast cancer	1.2e-05	0.000183	CcSEcCtD
Afatinib—Asthenia—Epirubicin—breast cancer	1.18e-05	0.00018	CcSEcCtD
Afatinib—Pruritus—Epirubicin—breast cancer	1.17e-05	0.000177	CcSEcCtD
Afatinib—Dizziness—Methotrexate—breast cancer	1.16e-05	0.000177	CcSEcCtD
Afatinib—Diarrhoea—Epirubicin—breast cancer	1.13e-05	0.000171	CcSEcCtD
Afatinib—Vomiting—Methotrexate—breast cancer	1.12e-05	0.00017	CcSEcCtD
Afatinib—Rash—Methotrexate—breast cancer	1.11e-05	0.000169	CcSEcCtD
Afatinib—Dermatitis—Methotrexate—breast cancer	1.11e-05	0.000168	CcSEcCtD
Afatinib—Headache—Methotrexate—breast cancer	1.1e-05	0.000167	CcSEcCtD
Afatinib—Asthenia—Doxorubicin—breast cancer	1.09e-05	0.000166	CcSEcCtD
Afatinib—Dizziness—Epirubicin—breast cancer	1.09e-05	0.000165	CcSEcCtD
Afatinib—Pruritus—Doxorubicin—breast cancer	1.08e-05	0.000164	CcSEcCtD
Afatinib—Vomiting—Epirubicin—breast cancer	1.05e-05	0.000159	CcSEcCtD
Afatinib—Nausea—Methotrexate—breast cancer	1.05e-05	0.000159	CcSEcCtD
Afatinib—Diarrhoea—Doxorubicin—breast cancer	1.04e-05	0.000158	CcSEcCtD
Afatinib—Rash—Epirubicin—breast cancer	1.04e-05	0.000158	CcSEcCtD
Afatinib—Dermatitis—Epirubicin—breast cancer	1.04e-05	0.000158	CcSEcCtD
Afatinib—Headache—Epirubicin—breast cancer	1.03e-05	0.000157	CcSEcCtD
Afatinib—Dizziness—Doxorubicin—breast cancer	1.01e-05	0.000153	CcSEcCtD
Afatinib—Nausea—Epirubicin—breast cancer	9.78e-06	0.000149	CcSEcCtD
Afatinib—Vomiting—Doxorubicin—breast cancer	9.69e-06	0.000147	CcSEcCtD
Afatinib—Rash—Doxorubicin—breast cancer	9.61e-06	0.000146	CcSEcCtD
Afatinib—Dermatitis—Doxorubicin—breast cancer	9.6e-06	0.000146	CcSEcCtD
Afatinib—Headache—Doxorubicin—breast cancer	9.55e-06	0.000145	CcSEcCtD
Afatinib—Nausea—Doxorubicin—breast cancer	9.05e-06	0.000138	CcSEcCtD
Afatinib—LCK—Immune System—CDKN1B—breast cancer	6.18e-07	8.12e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—STAT3—breast cancer	6.18e-07	8.12e-06	CbGpPWpGaD
Afatinib—LCK—Disease—ERBB2—breast cancer	6.16e-07	8.1e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—LEP—breast cancer	6.16e-07	8.09e-06	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—HRAS—breast cancer	6.13e-07	8.05e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NQO1—breast cancer	6.12e-07	8.04e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—SLC2A1—breast cancer	6.12e-07	8.04e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—JUN—breast cancer	6.11e-07	8.02e-06	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—IL6—breast cancer	6.11e-07	8.02e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CAV1—breast cancer	6.1e-07	8.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ESR1—breast cancer	6.1e-07	8.02e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CB—breast cancer	6.08e-07	7.99e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MTOR—breast cancer	6.08e-07	7.99e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CASP3—breast cancer	6.08e-07	7.99e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL1B—breast cancer	6.07e-07	7.98e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CD4—breast cancer	6.07e-07	7.98e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL2—breast cancer	6.07e-07	7.97e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—KRAS—breast cancer	6.07e-07	7.97e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—CTNNB1—breast cancer	6.06e-07	7.96e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL2—breast cancer	6.05e-07	7.95e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KDR—breast cancer	6.03e-07	7.93e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—FN1—breast cancer	6.03e-07	7.92e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PTGS2—breast cancer	6.03e-07	7.92e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—KRAS—breast cancer	5.98e-07	7.85e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP3A4—breast cancer	5.97e-07	7.84e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NFKBIA—breast cancer	5.96e-07	7.82e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1B—breast cancer	5.92e-07	7.78e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—CDKN1A—breast cancer	5.92e-07	7.78e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CCND1—breast cancer	5.92e-07	7.77e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PTEN—breast cancer	5.91e-07	7.76e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—MAPK3—breast cancer	5.91e-07	7.76e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—JUN—breast cancer	5.91e-07	7.76e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOTCH1—breast cancer	5.9e-07	7.75e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—JUN—breast cancer	5.89e-07	7.73e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ESR1—breast cancer	5.88e-07	7.73e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1B1—breast cancer	5.87e-07	7.71e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CTNNB1—breast cancer	5.86e-07	7.7e-06	CbGpPWpGaD
Afatinib—EGFR—Innate Immune System—AKT1—breast cancer	5.85e-07	7.68e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—CTNNB1—breast cancer	5.84e-07	7.67e-06	CbGpPWpGaD
Afatinib—ABCB1—Transmembrane transport of small molecules—RAF1—breast cancer	5.84e-07	7.66e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—FN1—breast cancer	5.81e-07	7.63e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK8—breast cancer	5.78e-07	7.59e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CG—breast cancer	5.77e-07	7.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—APC—breast cancer	5.77e-07	7.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KIT—breast cancer	5.77e-07	7.58e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—HRAS—breast cancer	5.77e-07	7.57e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HSP90AA1—breast cancer	5.75e-07	7.56e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MMP9—breast cancer	5.75e-07	7.55e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NFKBIA—breast cancer	5.74e-07	7.54e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—CDKN1A—breast cancer	5.73e-07	7.52e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PTEN—breast cancer	5.71e-07	7.5e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1B—breast cancer	5.71e-07	7.5e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—CDKN1A—breast cancer	5.71e-07	7.5e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—EGF—breast cancer	5.7e-07	7.49e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PTEN—breast cancer	5.69e-07	7.48e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOTCH1—breast cancer	5.68e-07	7.47e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CD—breast cancer	5.66e-07	7.44e-06	CbGpPWpGaD
Afatinib—LCK—Innate Immune System—AKT1—breast cancer	5.63e-07	7.4e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—EGFR—breast cancer	5.62e-07	7.38e-06	CbGpPWpGaD
Afatinib—EGFR—Adaptive Immune System—AKT1—breast cancer	5.61e-07	7.37e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CTNNB1—breast cancer	5.6e-07	7.35e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOA1—breast cancer	5.6e-07	7.35e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—ALB—breast cancer	5.59e-07	7.34e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK8—breast cancer	5.59e-07	7.34e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—PIK3CA—breast cancer	5.57e-07	7.32e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK8—breast cancer	5.57e-07	7.32e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KIT—breast cancer	5.56e-07	7.3e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CG—breast cancer	5.56e-07	7.3e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—APC—breast cancer	5.56e-07	7.3e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—MAPK3—breast cancer	5.52e-07	7.26e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—IL6—breast cancer	5.52e-07	7.25e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP19A1—breast cancer	5.52e-07	7.24e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—STK11—breast cancer	5.52e-07	7.24e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGF—breast cancer	5.5e-07	7.22e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—PIK3CA—breast cancer	5.49e-07	7.21e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—SRC—breast cancer	5.48e-07	7.2e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—CDKN1A—breast cancer	5.47e-07	7.18e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PTEN—breast cancer	5.45e-07	7.16e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—BRAF—breast cancer	5.42e-07	7.12e-06	CbGpPWpGaD
Afatinib—LCK—Adaptive Immune System—AKT1—breast cancer	5.41e-07	7.11e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CTNNB1—breast cancer	5.39e-07	7.08e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—TP53—breast cancer	5.39e-07	7.08e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—NOS3—breast cancer	5.35e-07	7.02e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—TP53—breast cancer	5.31e-07	6.98e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—KRAS—breast cancer	5.31e-07	6.97e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—SRC—breast cancer	5.3e-07	6.96e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—STAT3—breast cancer	5.28e-07	6.94e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IGF1—breast cancer	5.28e-07	6.94e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—SRC—breast cancer	5.28e-07	6.94e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT2—breast cancer	5.28e-07	6.93e-06	CbGpPWpGaD
Afatinib—LCK—Disease—CDKN1A—breast cancer	5.27e-07	6.92e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PTEN—breast cancer	5.26e-07	6.9e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—BRAF—breast cancer	5.23e-07	6.86e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—VEGFA—breast cancer	5.16e-07	6.78e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—HRAS—breast cancer	5.16e-07	6.77e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—COMT—breast cancer	5.13e-07	6.74e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—STAT3—breast cancer	5.11e-07	6.71e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTP1—breast cancer	5.1e-07	6.7e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—STAT3—breast cancer	5.09e-07	6.69e-06	CbGpPWpGaD
Afatinib—IRAK1—Immune System—AKT1—breast cancer	5.09e-07	6.69e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IGF1—breast cancer	5.09e-07	6.69e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT2—breast cancer	5.09e-07	6.68e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—HRAS—breast cancer	5.08e-07	6.67e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CD—breast cancer	5.07e-07	6.66e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—SRC—breast cancer	5.06e-07	6.64e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—MAPK3—breast cancer	5.05e-07	6.63e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—HMOX1—breast cancer	5.03e-07	6.61e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ITPR1—breast cancer	5.02e-07	6.6e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SERPINE1—breast cancer	5.02e-07	6.59e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—KRAS—breast cancer	4.97e-07	6.52e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—IL6—breast cancer	4.94e-07	6.48e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CB—breast cancer	4.94e-07	6.48e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTGS2—breast cancer	4.89e-07	6.42e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CD—breast cancer	4.89e-07	6.42e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MAPK3—breast cancer	4.88e-07	6.41e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—STAT3—breast cancer	4.88e-07	6.41e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—PIK3CA—breast cancer	4.88e-07	6.41e-06	CbGpPWpGaD
Afatinib—LCK—Disease—SRC—breast cancer	4.87e-07	6.4e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—MAPK3—breast cancer	4.86e-07	6.39e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—IL6—breast cancer	4.86e-07	6.39e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SERPINE1—breast cancer	4.83e-07	6.35e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—NOS3—breast cancer	4.79e-07	6.29e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—MYC—breast cancer	4.75e-07	6.24e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—TYMS—breast cancer	4.74e-07	6.23e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TGFB1—breast cancer	4.74e-07	6.22e-06	CbGpPWpGaD
Afatinib—LCK—Disease—STAT3—breast cancer	4.7e-07	6.18e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NCOR1—breast cancer	4.69e-07	6.16e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PLA2G4A—breast cancer	4.69e-07	6.16e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GSTM1—breast cancer	4.69e-07	6.16e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MAPK3—breast cancer	4.66e-07	6.12e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—EGFR—breast cancer	4.64e-07	6.1e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—EGFR—breast cancer	4.63e-07	6.08e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—NOS3—breast cancer	4.61e-07	6.06e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—PIK3CA—breast cancer	4.56e-07	5.99e-06	CbGpPWpGaD
Afatinib—ERBB2—Signaling Pathways—AKT1—breast cancer	4.55e-07	5.98e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MDM2—breast cancer	4.54e-07	5.97e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—KRAS—breast cancer	4.54e-07	5.96e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—MYC—breast cancer	4.53e-07	5.95e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RAF1—breast cancer	4.53e-07	5.95e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—TGFB1—breast cancer	4.52e-07	5.94e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—HRAS—breast cancer	4.51e-07	5.93e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—RELA—breast cancer	4.51e-07	5.92e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MAPK3—breast cancer	4.49e-07	5.9e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—GPX1—breast cancer	4.49e-07	5.9e-06	CbGpPWpGaD
Afatinib—ERBB4—Signaling Pathways—AKT1—breast cancer	4.49e-07	5.89e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—ERBB2—breast cancer	4.48e-07	5.88e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CYP1A1—breast cancer	4.45e-07	5.84e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CB—breast cancer	4.42e-07	5.81e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MTOR—breast cancer	4.42e-07	5.81e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ERCC2—breast cancer	4.41e-07	5.79e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—KRAS—breast cancer	4.39e-07	5.76e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MDM2—breast cancer	4.38e-07	5.75e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—KRAS—breast cancer	4.37e-07	5.74e-06	CbGpPWpGaD
Afatinib—LCK—Disease—MYC—breast cancer	4.37e-07	5.74e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RAF1—breast cancer	4.36e-07	5.73e-06	CbGpPWpGaD
Afatinib—LCK—Disease—TGFB1—breast cancer	4.36e-07	5.72e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—RELA—breast cancer	4.34e-07	5.71e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—IL6—breast cancer	4.32e-07	5.67e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—ERBB2—breast cancer	4.32e-07	5.67e-06	CbGpPWpGaD
Afatinib—LCK—Disease—EGFR—breast cancer	4.27e-07	5.61e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PTEN—breast cancer	4.26e-07	5.6e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MTOR—breast cancer	4.26e-07	5.6e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CB—breast cancer	4.26e-07	5.6e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CXCL8—breast cancer	4.25e-07	5.58e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—HRAS—breast cancer	4.22e-07	5.54e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—KRAS—breast cancer	4.19e-07	5.5e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—PIK3CA—breast cancer	4.17e-07	5.47e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1B—breast cancer	4.15e-07	5.45e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—MTHFR—breast cancer	4.14e-07	5.44e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CXCL8—breast cancer	4.09e-07	5.38e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CASP3—breast cancer	4.07e-07	5.34e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL2—breast cancer	4.06e-07	5.33e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—IL6—breast cancer	4.04e-07	5.31e-06	CbGpPWpGaD
Afatinib—LCK—Disease—KRAS—breast cancer	4.04e-07	5.3e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—PIK3CA—breast cancer	4.03e-07	5.29e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—PIK3CA—breast cancer	4.02e-07	5.28e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1B—breast cancer	4e-07	5.25e-06	CbGpPWpGaD
Afatinib—ABL1—Immune System—AKT1—breast cancer	3.98e-07	5.23e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CCND1—breast cancer	3.96e-07	5.2e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—JUN—breast cancer	3.95e-07	5.19e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CTNNB1—breast cancer	3.92e-07	5.15e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CASP3—breast cancer	3.92e-07	5.15e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL2—breast cancer	3.91e-07	5.14e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—TP53—breast cancer	3.9e-07	5.12e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—HRAS—breast cancer	3.86e-07	5.07e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—PIK3CA—breast cancer	3.85e-07	5.05e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MMP9—breast cancer	3.84e-07	5.05e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—CDKN1A—breast cancer	3.83e-07	5.03e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—CAV1—breast cancer	3.82e-07	5.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PTEN—breast cancer	3.82e-07	5.02e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CCND1—breast cancer	3.81e-07	5.01e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—JUN—breast cancer	3.81e-07	5e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CTNNB1—breast cancer	3.78e-07	4.96e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK8—breast cancer	3.74e-07	4.91e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—HRAS—breast cancer	3.73e-07	4.9e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling by GPCR—AKT1—breast cancer	3.73e-07	4.89e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—HRAS—breast cancer	3.72e-07	4.88e-06	CbGpPWpGaD
Afatinib—LCK—Disease—PIK3CA—breast cancer	3.71e-07	4.87e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MMP9—breast cancer	3.7e-07	4.86e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—IL6—breast cancer	3.69e-07	4.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—CDKN1A—breast cancer	3.69e-07	4.85e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PTEN—breast cancer	3.68e-07	4.84e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK8—breast cancer	3.6e-07	4.73e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—IL6—breast cancer	3.57e-07	4.69e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—HRAS—breast cancer	3.56e-07	4.68e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—IL6—breast cancer	3.56e-07	4.67e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—SRC—breast cancer	3.54e-07	4.65e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CG—breast cancer	3.48e-07	4.57e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—VEGFA—breast cancer	3.45e-07	4.53e-06	CbGpPWpGaD
Afatinib—LCK—Disease—HRAS—breast cancer	3.43e-07	4.51e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—STAT3—breast cancer	3.42e-07	4.49e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—SRC—breast cancer	3.41e-07	4.48e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—IL6—breast cancer	3.41e-07	4.48e-06	CbGpPWpGaD
Afatinib—EGFR—Immune System—AKT1—breast cancer	3.4e-07	4.47e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—VEGFA—breast cancer	3.32e-07	4.37e-06	CbGpPWpGaD
Afatinib—IRAK1—Signaling Pathways—AKT1—breast cancer	3.29e-07	4.32e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—STAT3—breast cancer	3.29e-07	4.32e-06	CbGpPWpGaD
Afatinib—LCK—Disease—IL6—breast cancer	3.28e-07	4.31e-06	CbGpPWpGaD
Afatinib—LCK—Immune System—AKT1—breast cancer	3.28e-07	4.31e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MAPK3—breast cancer	3.26e-07	4.29e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—MYC—breast cancer	3.17e-07	4.17e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TGFB1—breast cancer	3.17e-07	4.16e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MAPK3—breast cancer	3.15e-07	4.13e-06	CbGpPWpGaD
Afatinib—EGFR—Disease—AKT1—breast cancer	3.14e-07	4.13e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CD—breast cancer	3.06e-07	4.02e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—MYC—breast cancer	3.06e-07	4.02e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TGFB1—breast cancer	3.05e-07	4.01e-06	CbGpPWpGaD
Afatinib—LCK—Disease—AKT1—breast cancer	3.03e-07	3.98e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—ALB—breast cancer	3.02e-07	3.97e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—PIK3CA—breast cancer	3.01e-07	3.95e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—EGFR—breast cancer	2.99e-07	3.93e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—KRAS—breast cancer	2.93e-07	3.85e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—NOS3—breast cancer	2.89e-07	3.8e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—KRAS—breast cancer	2.83e-07	3.71e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—PIK3CA—breast cancer	2.69e-07	3.54e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CB—breast cancer	2.67e-07	3.5e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTGS2—breast cancer	2.64e-07	3.47e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—TP53—breast cancer	2.61e-07	3.42e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—PIK3CA—breast cancer	2.6e-07	3.41e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—TP53—breast cancer	2.51e-07	3.3e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—HRAS—breast cancer	2.49e-07	3.27e-06	CbGpPWpGaD
Afatinib—ABCG2—Metabolism—AKT1—breast cancer	2.46e-07	3.23e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—HRAS—breast cancer	2.4e-07	3.16e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—IL6—breast cancer	2.39e-07	3.13e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PTEN—breast cancer	2.31e-07	3.03e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—IL6—breast cancer	2.3e-07	3.02e-06	CbGpPWpGaD
Afatinib—EGFR—Signaling Pathways—AKT1—breast cancer	2.2e-07	2.89e-06	CbGpPWpGaD
Afatinib—LCK—Signaling Pathways—AKT1—breast cancer	2.12e-07	2.79e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—PIK3CA—breast cancer	1.63e-07	2.14e-06	CbGpPWpGaD
Afatinib—ABCB1—Metabolism—AKT1—breast cancer	1.33e-07	1.75e-06	CbGpPWpGaD
